Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, recently launched its ChrgD+ product, a water-soluble, multispectrum hemp oil in a powdered format powered by the company’s proprietary DehydraTECH(TM) technology for rapid CBD delivery (http://cnw.fm/a3Kr5). An article discussing the company reads, “The rapid biodelivery of CBD through DehydraTECH provides an avenue for safer, less-conspicuous consumption of CBD than inhaling it through smoke or vapor during a critical time when social acceptance of cannabis products is exploding age-old prohibitions but many legislative entities continue to struggle with regulatory issues on behalf of the public welfare. . . . ChrgD+ has been available in a limited number of retail stores throughout the Western United States, but the announcement that it is now available via commercial web delivery to locations where it can be legally consumed means that anyone has the potential to obtain it through the website www.ChrgD.life without having to travel. Limited-time promotional offers and product updates are also available through the site.”
To view the full article, visit http://cnw.fm/rn1CT
About Lexaria Bioscience Corp.
Lexaria is a global innovator in drug-delivery platforms. Its patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption, reduces time of onset, and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and more than 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
[email protected]